Negev Labs

Negev Labs is a venture studio based in Fort Lee, New Jersey, founded in 2022. It specializes in developing neuroplastogens, a next-generation class of therapies targeting unmet needs in neuropsychiatry, including depression, apathy, and neurodegeneration. The organization aims to bridge the $1.5 trillion acquisition gap in the pharmaceutical industry by in-licensing or acquiring drug candidates that already have human data, thus enabling capital-efficient trials designed for early efficacy and scalable solutions.

Negev Labs focuses on developing neuroplastogens, which are non-hallucinogenic therapies designed to address significant unmet needs in neuropsychiatry. The organization emphasizes capital-efficient trials that demonstrate early efficacy, aiming for scalable, clinic-ready solutions.

Negev Labs offers a unique venture studio model that emphasizes capital-efficient development of human-data-backed drug candidates, aiming for rapid licensing or acquisition. The organization leverages its expertise in CNS and psychedelics to build companies around overlooked assets, providing a pathway to commercialization for innovative therapies.